Cancer Gene Modification
Cancer Gene Modification - Related Videos
11:16
Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells
0 Views •
Cited by 9 •
2019
The goal of this protocol is to isolate nonhuman primate CD34+ cells from primed bone marrow, to gene-modify these cells with lentiviral vectors, and to prepare a product for infusion into the autologous host. The total protocol length is approximately 48 h.
02:32
Histone Modification
0 Views •
2020
The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression. Acetylation The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
13:10
DNA Vector-based RNA Interference to Study Gene Function in Cancer
0 Views •
Cited by 26 •
2012
RNA interference (RNAi) possesses many advantages over gene knockout and has been broadly used as a tool in gene functional studies. The invention of DNA vector-based RNAi technology has made long term and inducible gene knockdown possible, and also increased the feasibility of gene silencing in vivo.
13:20
Chromatin Immunoprecipitation (ChIP) to Assay Dynamic Histone Modification in Activated Gene Expression in Human Cells
0 Views •
Cited by 11 •
2010
This protocol describes how chromatin immunoprecipitation (ChIP) is used to study the dynamic alterations to the chromatin template that regulate transcription induced by a signal transduction pathway.
11:50
Genome-Wide Mapping of Histone Modifications and Transcription Factor Binding Sites in Neuroendocrine Small Cell Lung Cancer Cell Lines Using CUT&RUN
0 Views •
2026
An optimized Cleavage Under Targets and Release Using Nuclease followed by next generation sequencing (CUT&RUN-seq) protocol is described for neuroendocrine small cell lung cancer cell lines. It enables genome-wide mapping of various histone modifications and transcription factor (e.g. E2F7) binding sites to investigate epigenetic and transcriptional deregulation in SCLC pathobiology.
FAQs
A guide RNA directs the CRISPR-Cas nuclease to a selected DNA sequence, where the nuclease makes a cut. Cellular repair can then disrupt the targeted gene, correct an existing sequence, or incorporate new genetic information. The resulting outcome depends on the repair process and the intended design, allowing researchers to connect specific genetic changes with cancer-cell behavior or treatment response.
Altering oncogenes or tumor-suppressor genes helps researchers test whether particular genes contribute to cancer development or progression. These experiments can reveal how genetic changes affect tumor biology and can distinguish genes that promote disease from those that normally restrain it. The findings support more precise disease models and help evaluate how genetic alterations influence responses to treatment.
CRISPR-Cas systems provide targeted DNA cutting directed by guide RNA, while viral vectors can deliver engineered genes into cells. These approaches address different parts of the modification process: one emphasizes sequence-directed editing, whereas the other emphasizes gene delivery. In either case, researchers must consider delivery effectiveness, editing accuracy, and control of unintended genetic effects.
Useful results depend on three linked considerations: whether the intended genetic sequence is changed accurately, whether the editing or engineered material reaches the relevant cells, and whether unintended effects remain controlled. If any of these conditions is inadequate, observed changes may be difficult to interpret. Careful attention to these factors strengthens conclusions about cancer mechanisms and treatment responses.
Researchers can modify cancer-directed therapeutic cells so their genetic properties support an intended treatment strategy. The modified cells are studied for how genetic changes alter their activity against cancer or their response to treatment conditions. This application extends gene modification beyond tumor cells themselves and illustrates how engineered cellular systems can be investigated as potential therapeutic approaches.
By changing selected cancer-related genes, researchers can create experimental models that test how those alterations influence tumor progression. These models help connect genetic events with disease behavior rather than examining genes in isolation. They also provide a way to compare modified cancer cells or therapeutic cells and to investigate how genetic changes affect responses to potential treatments.